Antengene announces approval for reimbursement of the drug XPOVIO® (selinexor) by the National Health Insurance Service in South Korea

– XPOVIO^® is the first XPO1 inhibitor approved for reimbursement by South Korea National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM).

– XPOVIO approval^® by the NHIS in South Korea is the fourth national reimbursement in Antengene’s markets after the continent China, Australia And Singapore.

– Additional refunds from XPOVIO^® in APAC markets are expected.

– Antengene has also submitted new drug applications (NDAs) in other ASEAN markets, including Thailand, Malaysia And Indonesiawhere approvals are expected in the second half of 2024.

SHANGHAI And HONG KONG, June 26, 2024 /PRNewswire/ — Antengene Corporation Limited (“Antenna“, SEHK: 6996.HK), a leading global innovative and commercial biopharmaceutical company dedicated to the discovery, development and commercialization of first-in-class and/or first-in-class anti-cancer drugs, announced today that South Korea The National Health Insurance Service (NHIS) approved reimbursement for XPOVIO^® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). XPOVIO^® will be officially included on the national list of reimbursed drugs South Korea on 1st of July2024.

MM, the second most common hematologic malignancy, is caused by dysregulated proliferation of plasma cells. Patients with MM face a range of challenges, including a high relapse rate, short survival, and limited treatment options. According to market data, the global MM market has exceeded 17 billion US dollars in 2023 and is expected to reach 26 billion US dollars by 2028, with a compound annual growth rate (CAGR) of 8.7%⁽¹⁾.

With a new mechanism of action, XPOVIO^® is the first orally available selective XPO1 inhibitor approved in the world. XPOVIO^® has a global commercial presence with approvals in more than 40 countries and regions.

To date, XPOVIO^® has already been included in health insurance coverage on the continent China, Australia And Singapore in APAC markets. With the latest approval from the NHIS in South KoreaXPOVIO^® is poised to become a new treatment option and will bring clinically meaningful survival benefits to more patients in need.

Antengene has already submitted NDAs for XPOVIO^® In Thailand, Malaysia And Indonesia for the treatment of patients with R/R MM and BR/R diffuse large cell lymphoma (R/R DLBCL).

About XPOVIO^® (selinexor)

XPOVIO^® is the world’s first orally available and approved selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, rapid onset of action and durable responses.

By blocking the nuclear export protein XPO1, XPOVIO^® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulatory proteins, and downregulate the levels of several oncogenic proteins.^® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reduce the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restore hormonal sensitivity by activating the glucocorticoid receptor (GR) pathway. To use its unique mechanism of action, XPOVIO^® is being evaluated for use in multiple combination regimens across a range of indications. Antengene is currently conducting several clinical studies on XPOVIO^® on the continent of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (three of these studies are being conducted jointly by Antengene and Karyopharm Therapeutics Inc. (Nasdaq: KPTI)).

About Antengene

Antengene Corporation Limited (“Antengene”SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative, first-in-class/best-in-class therapeutic products, for the treatment of hematologic malignancies and solid tumors, by realizing its vision of “Treating patients across borders”.

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages from clinical to commercial, including 6 with global rights and 3 with rights for the APAC region. To date, Antengene has obtained 29 Investigational New Drug (IND) approvals in the United States and Asiaand submitted 10 new drug applications (NDAs) in several Asia Pacific markets, with the NDA for XPOVIO^® (selinexor) already approved in mainland China ChinaTaiwan China, Hong Kong ChinaMacau China, South Korea, Singapore And Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made. made or to reflect the occurrence of unforeseen events. events. You should read this article in its entirety and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements or references to our intentions or those of any of our directors or our company are made as of the date of this article. Each of these intentions may change in light of future developments. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statements, please see Other Risks and Uncertainties described in the Company’s Annual Report for the current fiscal year. December 31, 2023and the documents were then submitted to the Hong Kong Stock Exchange.

Reference:

⁽¹⁾ Global Multiple Myeloma Treatment Market Size, Share and Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation), by Region and Segment Forecast, 2023-2028 .

For more information please contact:

Investor contacts:
Donald Lung
E-mail: (email protected)
Mobile: +86 18420672158

PR contacts:
Peter Qian
E-mail: (email protected)
Mobile: +86 13062747000

SOURCE Antengene Corporation Limited